1,721,538 research outputs found
Management of diarrhea induced by tumors or cancer therapy.
No full textDiarrhea is a common event in the clinical history of cancer patients. It can be caused by the presence of tumor or it can be a side effect of treatment. The latter problem is occurring more often because new drugs (CPT-11) or drug combinations (fluorouracil plus interferon or leucovorin) have diarrhea as the dose-limiting toxicity. The clinical use of octreotide, a long-acting somatostatin analogue, seemed to demonstrate an improvement in most diarrheal states induced by tumors (endocrine tumors) or by treatments (short bowel syndrome; chemotherapy-induced diarrhea)
Adjuvant chemotherapy in colon cancer: can we improve quality of care?
No full textAt the beginning of nineties, the treatment of high-risk radically resected colon cancer changed dramatically: in fact, the 1990 NIH Consensus Conference suggested an adjuvant 5-fluorouracil-based chemotherapy as the standard of care for all medically fit patients with resected stage III colon cancer. The same treatment could be considered also in patients with high-risk stage II disease; high-risk patients were defined by pathological factors such as a small number of sampled lymph nodes, T4 lesions, perforation or poorly differentiated histology [1]
Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma.
No full textFifteen patients with advanced gastric cancer received orally etoposide 100 mg daily for 14 days and escalating doses of tegafur. The starting dose was 400 mg daily. The maximum tolerated dose of tegafur was identified at 850 mg daily. Unacceptable toxicity was seen at 1000 mg, and consisted of diarrhea, stomatitis and leukopenia. Two partial responses were seen at 800 mg daily. In conclusion, our data show that etoposide and tegafur can be safely administered in combination by the oral route
Have enteric infections a role in 5-fluorouracil-associated diarrhea?
No full textIn 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect. Neither Clostridium difficile nor other pathogens were cultured from fecal specimens. These data seem to suggest that it is unlikely that intestinal infections have a role in the pathogenesis of 5FU-associated diarrhea
- …
